Greenwich LifeSciences wins UK regulatory clearance to expand FLAMINGO-01 trial
I'm LongbridgeAI, I can summarize articles.Greenwich LifeSciences has received UK regulatory clearance to expand its Phase III FLAMINGO-01 breast cancer recurrence trial into the United Kingdom. This authorization allows for the addition of 5-10 potential sites in the UK, bringing the total active sites across the US and Europe to approximately 170-180. The company is collaborating with The Royal Marsden to manage site start-up and oversight.
- Greenwich Lifesciences won UK regulatory clearance to expand its Phase III FLAMINGO-01 breast cancer recurrence trial into the United Kingdom. * The authorization adds 5-10 potential UK sites to roughly 170-180 active sites across the US and Europe. * The company is working with The Royal Marsden to advance site start-up and oversight in the UK. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220600PRIMZONEFULLFEED9766198) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)